Market news
Detailed price information for Maxcyte Inc (MXCT-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
MaxCyte Inc (MXCT) navigates a transitional quarter with a landmark Genentech deal and robust CASGEVY royalties, positioning for renewed growth in the second half of 2026.
Moby summary of MaxCyte, Inc.'s Q2 2026 earnings call
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectation
MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Maxcyte Inc (MXCT-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.